NSC23005 sodium is a novel and effective p18 inhibitor (ED50=5.21 nM) that promotes Hematopoietic stem cells (HSCs) expansion in both murine and human models.

p18INK4C:5.21 nM (ED50)

NSC23005 sodium is a novel class of INK4C (p18INK4C or p18) small molecule inhibitor (p18SMIs), which is initially found by in silico 3D screening. NSC23005 sodium shows the most potent bioactivity in hematopoietic stem cells (HSCs) expansion (ED50=5.21 nM). Notably, NSC23005 sodium does not show significant cytotoxicity toward 32D cells or HSCs, nor does it augment leukemia cell proliferation. NSC23005 sodium (ED50=5.21 nM), shows no activity in promoting the proliferation of leukemia cells.

NSC23005 sodium selectively promotes HSC division by inhibiting p18, thereby activating CDK4/6. This novel and effective p18 inhibitor enhances HSC expansion in both murine and human models without significant cytotoxicity toward HSCs, and it does not augment leukemia cell proliferation.

NSC23005 sodium is dissolved in DMSO and stored, and then diluted with appropriate medium before use[1]. c-Kit enriched bone marrow (BM) cells are cultured for 5 days with cytokine combination plus NSC23005 sodium or DMSO. As positive controls, primary uncultured bone marrow cells are treated by ultraviolet radiation (UV) for 10 minutes prior to the staining process for apoptosis analysis. Apoptosis and cell death are measured by AnnexinV and DAPI staining in the Annexin V-FITC Apoptosis Detection Kit. Apoptosis is measured on an FACS analyzer. The data is analyzed using FlowJo software[1].